In immunodeficiency, an increased sarcoma risk is confirmed for Kaposi's sarcoma. Whether rates of other sarcoma subtypes are elevated in the setting of immunodeficiency is not known. We therefore reviewed published case reports on HIV and AIDS patients and organ transplant recipients with sarcomas. For comparison, we assessed sarcomas in the U.S. general population using Surveillance Epidemiology End Results (SEER) data.
INTRODUCTION
A dramatic eruption of an otherwise rare cancer, Kaposi sarcoma, in young men in San Francisco heralded the HIV epidemic in the USA. The incidence of Kaposi sarcoma rose from approximately 0.5 per 100 000 people in 1975 to a peak of 33.3 in the late 1980s to the early 1990s [1] . Reports describing Kaposi sarcoma in solid-organ transplant recipients also linked this sarcoma with immunosuppression [2] . Later, systematic analyses of population-based registry data clearly demonstrated a several thousand-fold increased Kaposi sarcoma risk in people with AIDS compared to the general population [3] .
The incidence of as many as 20 distinct cancers is elevated in people with HIV infection and in solidorgan transplant recipients [4] , and the commonality in the spectrum of malignancies in these two immunosuppressed conditions is striking. Risk is most increased for cancers with an infectious cause, including those caused by oncogenic viruses such as human herpesvirus 8 (HHV-8, linked to Kaposi sarcoma), human papillomavirus (HPV, linked to anogenital cancers), Epstein-Barr virus (EBV, linked to non-Hodgkin and Hodgkin lymphomas), hepatitis B and hepatitis C viruses (HBV and HCV, linked to liver cancer), and Merkel cell polyomavirus (MCPyV, linked to Merkel cell carcinoma) [4] .
Sarcomas are diverse and include more than 50 distinct histological subtypes originating from connective tissues, including fibrous tissue, muscle, bone, cartilage, fat, blood vessels, and nerves [5] . However, the entire group of sarcomas together account for less than 1% of all malignancies. Although sarcomas occur across all ages, there are age-associated peaks in incidence specific for distinct entities. Rhabdomyosarcoma and Ewing sarcoma are both pediatric cancers, the former occurring in the first decade of life and the latter in the second decade. In contrast, liposarcomas and leiomyosarcomas most often occur in adults [6] .
The rarity, diversity, and age-dependency of specific sarcomas make it difficult to single out histological subcategories that are increased in people with immunosuppression, particularly if these increases are much smaller than observed for Kaposi sarcoma. In a prior analysis of population-based HIV and AIDS and cancer registry data, Biggar et al. [7] demonstrated an excess risk of leiomyosarcomas in children with AIDS. Over the past decade, other reports have described an excess of leiomyosarcomas in children with HIV or following organ transplantation [8] [9] [10] .
Whether other sarcoma subtypes are affected by immunosuppression is unclear. Even with large population-based registries [11] , the sensitivity of identifying an elevated risk of uncommon cancers depends upon the magnitude of the association, the incidence of these cancers in the general population, and the categorization of cancer types. Linkage-based studies of HIV and cancer have typically categorized cancers by site. As sarcomas can arise within multiple organs, this approach could have masked an elevated risk of sarcomas.
For these reasons, case reports remain an important source for understanding the spectrum of cancers in immunocompromised populations and ascertaining clues into cancer cause. To identify sarcomas that occur frequently in immunosuppressed populations and describe the characteristics of these sarcomas, we systematically reviewed published case reports and case series to catalog sarcomas reported in people with HIV infection and recipients of solid-organ transplants.
LITERATURE REVIEW APPROACH
We conducted a literature review using PubMed and references cited within published articles to compile case reports of all sarcomas, excluding Kaposi sarcoma, in people with HIV or a solid-organ transplant. Our PubMed search strategy included combinations of the following keywords: organ transplantation, malignancy, de-novo malignancy, immunosuppression, immunodeficiency, HIV, AIDS, and sarcoma. We also searched with names of specific sarcoma subtypes (e.g., leiomyosarcoma and osteosarcoma). We excluded studies of recipients of bone marrow transplants or congenital immunodeficiency syndromes, and articles not published in English.
Sarcomas were categorized into widely accepted histologic subtypes. To identify over-representation or under-representation of specific sarcoma subtypes in people with immunodeficiency, we compared the relative proportions of these subtypes reported in people with HIV or solid-organ transplants with the distribution in the general population. General population counts for sarcoma subtypes were obtained from the U.S. Surveillance, Epidemiology, and End Results database (SEER 17 regions, 1974-2008) [12] using International Classification of Diseases for Oncology morphology codes [13] .
In cataloging leiomyosarcoma cases, case reports with a diagnosis of EBV-associated smooth muscle tumor were categorized as leiomyosarcomas. We also compared the age distribution of case reports of leiomyosarcomas in people with immunodeficiency with leiomyosarcomas in SEER (histology code 8890, regardless of site). Finally, for comparison, we also captured case reports of leiomyomas in HIV-infected people and transplant recipients, which were analyzed separately. or recipients of solid-organ transplants (n ¼ 101) (Table 1 ). In both immunodeficient populations, more than half of the reported sarcomas were leiomyosarcoma. Fifty-four leiomyosarcomas occurred in solid-organ transplant recipients [10,14-56] and 47 occurred in people with HIV . Thus, 57.8% of all sarcomas reported in immunodeficient hosts were leiomyosarcomas. In comparison, in the U.S. general population (SEER data), only 16.9% of non-Kaposi sarcoma were leiomyosarcomas ( Table 1) .
The sex distribution of leiomyosarcoma cases was similar in people with HIV and transplant recipients. Of the 81 leiomyosarcomas for which EBV status was reported, EBV was detected in the tumor cells in 85 and 88% of cases in people with HIV and transplant recipients, respectively. EBV positive leiomyosarcomas were detected across all age groups. Among leiomyosarcoma cases with HIV infection, 94% had a prior AIDS diagnosis. Sixty-three percent of transplant-related leiomyosarcomas were reported among kidney recipients [16, . Figure 1a is a representation of the age distribution of case reports of leiomyosarcomas in HIV-infected individuals, transplant recipients, and the U.S. general population. In the general population, the number of leiomyosarcoma cases rises steeply with age, with 72% of cases occurring in people aged 50 years and older. In contrast, in people with HIV or transplant-associated immunodeficiency, leiomyosarcomas were reported across all age groups. Thirty-six percent of reports in HIV-infected individuals and 24% in transplant recipients were in children aged 0-9 years. In HIV-infected cases, this proportion diminished between the ages 10 and 29 years and peaked again, with 34% of cases occurring in 30-39 year olds. In transplant recipients, this second peak (19%) occurred in people aged 50 years or older.
Angiosarcomas also comprised a higher proportion of sarcomas in immunocompromised populations compared to the general population (6.7% of sarcomas in HIV-infected people and 18.0% in transplant recipients, vs. 3.8% in SEER; Table 1 ). We identified 23 cases of angiosarcomas, of which five cases were in HIV-infected adults (four men and one woman) [86] [87] [88] [89] . The remaining 18 cases were reported in kidney recipients [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] , and the vast majority were in men (n ¼ 16) ( Table 2 ). The median age at the diagnosis of angiosarcomas in transplant recipients was 43 years (range 24-71 years). The time to diagnosis following transplant ranged from 2 to 18 years. Eleven angiosarcomas in kidney transplant recipients (61%) arose at the site of an arteriovenous fistula. Of interest, an arteriovenous fistula was also the site of dermatofibrosarcoma protuberans (a subtype of fibrohistiocytic tumor) in three kidney recipients [106] [107] [108] . Thus, 14 sarcomas reported in kidney recipients occurred at an arteriovenous fistula, representing 20% of sarcomas in kidney recipients and 14% of sarcomas in transplant recipients overall.
Seventeen cases of fibrohistiocytic tumors were reported in immunodeficient individuals (Table 1 ) [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] . These include one case of angiomatoid fibrous histiocytoma in an HIV-infected person [106] ; five cases of dermatofibrosarcoma protuberans [107] [108] [109] [110] ; two cases of atypical fibroxanthoma [111, 112] ; and nine cases of malignant fibrohistiocytoma [112] [113] [114] [115] [116] [117] [118] [119] , eight of which were in transplant recipients. Fourteen of these 17 cases occurred in men. In comparison, 18.7% of sarcomas in the U.S. general population were fibrohistiocytic tumors.
Eight cases of rhabdomyosarcoma were reported (Table 1) , of which the majority (n ¼ 6) were in people with HIV [83, [120] [121] [122] [123] . Three of these rhabdomyosarcoma cases occurred in children, but both cases in transplant recipients were adults, one a 21-year-old female liver recipient [124] and the other a 67-year-old male kidney recipient [125] . Only a limited number of other sarcomas were described in the case literature (Table 1 ) .
Fifty leiomyomas were reported in HIV-infected individuals [9, 59, 69, [72] [73] [74] or transplant recipients [42, [182] [183] [184] [185] [186] [187] [188] [189] [190] , of which 80% were in HIVinfected individuals. Among HIV-infected people, 93% of leiomyomas occurred after an AIDS diagnosis. The male-to-female ratio of leiomyoma cases in HIV-infected individuals (2 : 1) differed from that in transplant recipients (1 : 1.5) and also differed from the ratio for leiomyosarcomas in HIV-infected individuals (1 : 1.5). Among transplant recipients, 80% of leiomyomas were reported in kidney recipients [42, [182] [183] [184] [185] [186] [187] [188] . Among the 24 leiomyomas for which EBV status was reported, EBV was detected in 100% of transplant-related leiomyomas but only 53% of HIV-related leiomyomas ( Table 3) . We queried leiomyoma and leiomyosarcoma reports for CD4 counts as a measure of immunosuppression. As shown in Fig. 1b , most cases were in people with CD4 counts below 50 cells/mm 3 . 
INTERPRETATIONS FROM CASE LITERATURE REVIEW
The objective of the current study was to identify subtypes of sarcomas other than Kaposi sarcoma that occur in immune-suppressed populations. Given the rarity and broad diversity of sarcomas, our hypothesis was that modestly elevated risks for rare sarcomas might have been missed in large registry-based studies of HIV-infected people and solidorgan transplant recipients. However, unusual individual cases or series of cases occurring in such individuals might have prompted clinicians to publish descriptive reports. Our literature review identified three sarcoma subtypes that are often reported in people with immunosuppression: leiomyosarcoma, angiosarcoma, and fibrohistiocytic tumors. Of these, only leiomyosarcoma and angiosarcoma were disproportionately represented in both HIV and transplant compared to the general population ( Table 1) .
The most commonly reported sarcoma in HIVinfected people and transplant recipients was leiomyosarcoma, with distinct age peaks in very young children, in young adults (for HIV), and older individuals greater than 50 (for transplant). EBV is not required for transformation, as leiomyomas and leiomyosarcomas that arise in immunocompetent individuals are not associated with EBV [191] , but our review suggests that immunosuppressionrelated leiomyosarcomas are highly associated with EBV across all ages. Of interest, EBV is also detected in muscle tumors in individuals with congenital immunodeficiency syndromes [192] . When present in leiomyosarcoma, EBV infection occurs prior to the clonal proliferation of tumor cells [15] , but most case reports indicate that EBV LMP-1, an important oncoprotein [193] , is not detectable [5, 15, 190] . EBV infection requires the expression of the cell-surface receptor CD21. Although some studies have demonstrated CD21 expression in smooth muscle tumors [9, 59] , other studies have not [186] . EBV infection of rare mesenchymal cells has been reported in immunocompetent hosts [194] , and high circulating levels of EBV during immunosuppression may more readily allow such infections.
The vast majority of HIV-infected individuals reported with leiomyosarcoma had AIDS, and CD4 cell counts were typically low among both leiomyosarcoma and leiomyoma patients. These observations highlight the importance of immunosuppression in facilitating the transformation of mesenchymal cells. EBV appears to be less often detected in leiomyomas than in leiomyosarcomas in the setting of HIV infection. Although the proportion of leiomyomas with missing data for EBV was large, the available reports point to a need for a systematic study of the molecular features of leiomyomas and leiomyosarcomas arising in immunosuppressed people.
Angiosarcomas are also frequently reported in people with immunodeficiency, raising the possibility of a viral cause. Early studies, based solely upon amplification of DNA by polymerase chain reaction PCR, suggested the presence of HHV-8 genome in angiosarcomas [195] , but more recent studies that have utilized in-situ methods to detect HHV-8 RNA or proteins have been mixed [85, [196] [197] [198] . Our review found a male predominance of angiosarcomas (20 male vs. 3 female reported cases). These sarcomas were also more frequently reported following kidney transplant than other organ transplants. Although this predominance may merely reflect that kidneys are the most commonly transplanted organ, it may instead be a clue to intrinsic factors that affect the development of angiosarcoma. Along these lines, an interesting feature of the angiosarcomas reported in kidney recipients is their apparent predilection to occur at the site of an arteriovenous fistula used for hemodialysis. Angiosarcomas have also been reported in hemodialysis patients who have not received a transplant [199 & ]. Inert foreign material can induce inflammation that might lead to the development of sarcomas, including angiosarcomas [200] . The milieu around an arteriovenous fistula is characterized by chronic venous stasis, altered capillary pressures, and tissue hypoxia, which may induce neovascularization and cellular proliferation. Angiosarcomas have also been documented within areas of lymphedema, as occur in the Stewart-Treves syndrome [201] , and they are a known complication of radiation exposure [202] .
Fibrohistocytic sarcomas reported in the case literature in people with HIV and organ transplants included dermatofibrosarcoma protuberans, atypical fibroxanthomas, and malignant fibrous histocytomas. Our review identified 17 fibrohistocytic sarcomas, the majority (n ¼ 14) of which occurred in men. However, these sarcomas represented only 5 and 13% of all sarcomas in people with HIV and in transplant recipients, respectively (Table 1 ).
An important limitation of our study is that it is solely based upon case reports. There is an inherent publication bias in these reports, in that investigators are more likely to report novel cases, such as those with unusual features, involvement of EBV, or occurrence in children. Therefore, our results should not be interpreted as a direct measure of risk associated with immunodeficiency or a complete characterization of the sarcomas that arise in immunosuppressed people. Nonetheless, the disproportionate representation of leiomyosarcomas that we observed is consistent with an increased risk for this sarcoma subtype observed in previous studies of immunosuppressed populations [7, 10] . Case report literature reviews also cannot incorporate a central pathology review or common standards for pathology diagnosis, which might introduce biases in the classification of sarcomas. The major strength of this report is our systematic review of the published literature, which provided a unique approach to assess rare sarcoma subtypes occurring in people with HIV and transplant recipients.
CONCLUSION
In summary, leiomyosarcomas and leiomyomas were frequently reported in HIV-infected people and organ transplant recipients, supporting an increased risk of this sarcoma in immunosuppressed people and highlighting the importance of EBV. The disproportionate occurrence of angiosarcomas may likewise reflect increased risks associated with immunodeficiency. Furthermore, among transplant recipients, angiosarcomas are most commonly reported in people with kidney transplants and might be correlated with an arteriovenous fistula. Additional studies are necessary to understand the contribution of immunodeficiency to the cause of these sarcomas.
